Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 in Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
NCT07261657Phase 1Recruiting
- Start
- Apr 2026
- Primary completion
- Sep 2030
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nogapendekin alfa inbakicept in synovial sarcoma (SS), myxoid liposarcoma (MLPS) and myxoid/round cell liposarcoma (MRCLS). Primary endpoints: Expansion of rare persisting transferred T-cell receptor therapy and Incidence of adverse events. Started Apr 2026; status: recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
synovial sarcoma (SS)myxoid liposarcoma (MLPS)myxoid/round cell liposarcoma (MRCLS)
Beyond the preview
Go deeper on NCT07261657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07261657.